Clinical Trial Update: FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation

View source ↗

Summary

This document provides an update on the Fibroleukin (FGL2) trial for preventing hepatitis C virus recurrence after liver transplantation, with the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Fibroleukin (FGL2)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Liver Transplantation, Hepatitis C | Status: UNKNOWN